EGLN1 and leukemia: Given the phenomena we observed, Selinexor, the inhibitor of CRM1, was administered, and it proved that it could effectively cause the accumulation of PHD2 in the nucleus and decrease the protein levels of PHD2 and HIF-1α in the leukemia cells under hypoxic conditions.